Cadila Healthcare rises on launching Saroglitazar Magnesium

Innovation-driven global pharmaceutical company, Zydus Cadila announced on Wednesday that Drug Controller General of India (DCGI) has approved its new drug application (NDA) for Saroglitazar Mgnesium, a treatment used for non-alcoholic fatty liver disease (NAFLD). 

Saroglitazar Mg is the first medicine used for the treatment of NAFLD. This approval for NAFLD, along with either of the co-morbidities (obesity, type 2 Diabetes Mellitus, Dyslipidemia) would provide physicians with a viable treatment option.  

In India, almost 25 per cent-30 per cent of the population is estimated to be suffering from NAFLD. 

Cadila Healthcare is an integrated pharmaceutical company with business encircling the entire value chain in the research, development, production, marketing & distribution of pharmaceutical products.  

During the first half of the trading session i.e., around 11.30 am, the stock of Cadila Healthcare was trading 0.25 per cent higher at Rs 480.20. The share recorded an intraday high of Rs 483.80 and an intraday low of Rs 476 on BSE.